Combination treatment for advanced vulvar cancer that can't be surgically removed

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I trial investigates the safety and optimal dosage of nelfinavir, an antiviral drug, when used alongside cisplatin and external beam radiation therapy for patients with locally advanced vulvar cancer that is not amenable to surgical removal. The study aims to assess the side effects and dose-limiting toxicities of this combination therapy. Patients will receive nelfinavir orally, cisplatin intravenously, and undergo radiation therapy over an 8-week period, with follow-up assessments for recurrence and survival outcomes. The trial also explores biological markers related to the cancer's progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with primary, previously untreated, histologically confirmed invasive carcinoma of the vulva (any cell type) not amenable to surgical excision. Clinical stages T2-T4, N0-3, M0. Hematoxylin \& eosin (H \& E) stained slide showing documentation of the primary invasive cancer is required. All specimens of primary tumor require documentation of type
* Absolute neutrophil count (ANC) \>= 1,500/microliter (performed within 28 days from signing consent form)
* Platelet count \>= 100,000/microliter (performed within 28 days from signing consent form)
* Creatinine \< 2.0 mg/dL (performed within 28 days from signing consent form)
* Total bilirubin =\< 1.5 times normal (performed within 28 days from signing consent form)
* Glutamic-oxaloacetic transaminase (SGOT) =\< 3 times normal (performed within 28 days from signing consent form)
* Patients with an Eastern Cooperative Oncology Group/Gynecologic Oncology Group (ECOG/GOG) performance status of 0, 1, or 2
* Patients with ureteral obstruction must be treated with stent or nephrostomy tube
* Patients must be consented within twelve (12) weeks of diagnosis or must be restaged
* Patients of childbearing potential must use an effective form of birth control. "Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive measures should be used during therapy with VIRACEPT."
* Confirmed seronegative HIV status within 3 months of signing consent
* Patients must have signed an approved informed consent and authorization permitting release of personal health information

Exclusion Criteria:

* Patients with stage T1N0 disease
* Patients who have known metastases to other organs outside the radiation field at the time of the original clinical and surgical staging
* Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy
* Patients with septicemia or severe infection
* Patients who have circumstances that will not permit completion of this study or the required follow-up
* Patients who are pregnant at the time of diagnosis and do not wish pregnancy termination prior to initiation of treatment
* Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
* Patients with other concomitant malignancies (with the exception of non-melanoma skin cancer), who had (or have) any evidence of other cancer present within the last 5 years
* Patients with gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
* Patients with poorly controlled diabetes mellitus despite medication
* Patients taking anti-arrhythmic agents such as amiodarone, quinidine, rifampin, ergot derivatives such as ergotamine, St John's wort, human menopausal gonadotropin (HMG)-CoA reductase inhibitors such as lovastatin, neuroleptic such as pimozide, sedatives such as midazolam and triazolam among other CYP3A4 and CYP2C19 substrates
* Patients with phenylketonuria
* Patients with estimated glomerular filtration rate (eGFR) \< 30

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Lilie L Lin — M.D. Anderson Cancer Center
• Study coordinator: Lilie L Lin
• Email: lllin@mdanderson.org
• Phone: 713-563-2300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Combining chemotherapy with immunotherapy for older adults with advanced lung cancer

  This study is testing if adding chemotherapy to immunotherapy can help older adults with advanced lung cancer live longer and feel better compared to just using immunotherapy alone.

  Recruiting at 271 sites Phase 3 National Cancer Institute (NCI) · Fayetteville, Arkansas and 329 other locations · NCT06096844

• Combining SX-682 and Pembrolizumab for Advanced Lung Cancer Treatment

  This study is testing if a new oral medication called SX-682, when combined with the IV drug pembrolizumab, can help people with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT05570825

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Using papaverine with chemoradiation to treat advanced non-small cell lung cancer

  This study is testing the best dose of papaverine combined with chemotherapy and radiation to see if it helps people with advanced non-small cell lung cancer live longer and control their tumors better.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Duarte, California and 1 other locations · NCT05136846

• Assessing heart health in lung cancer patients receiving personalized chemoradiation

  This study is testing how personalized chemoradiation treatment for lung cancer affects heart health in patients and if adjusting the treatment can help reduce heart disease risk.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05010109

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.